• Home  
  • Safety questions arise after Helus depression study
Safety questions arise after Helus depression study
- Health

Safety questions arise after Helus depression study

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. A psychedelic drug candidate from Helus

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

A psychedelic drug candidate from Helus Pharma significantly helped people with major depression in a Phase 3 trial, the company said Monday, but a number of serious adverse events in the study raised questions about the safety of the treatment.

At six weeks, people taking the drug in addition to their standard antidepressants experienced a reduction of 19.5 points on a depression rating scale called the MADRS, while the placebo group had a 11.9-point reduction.

At 12 weeks, the effect was largely maintained, with the treatment group seeing a 16.9-point reduction and the placebo group experiencing a 9.9-point reduction. The differences between the two groups were all statistically significant.

STAT+ Exclusive Story





This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Source: www.statnews.com

About Us

Toolq Media Is a Global News Platform Covering the Latest Developments and Breaking Stories from Around The World, Including World News, Business, Finance, Technology, Health, Politics, Science, Entertainment, Sports, and More.

Toolq

Toolq @2026. All Rights Reserved.